Cowen and Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Cowen and Company’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,121	Closed	-$85K	–	636
2021 Q3	$85K	Buy	+5,121	New	+$98.7K	﹤0.01%	342
2021 Q2	–	Sell	-7,500	Closed	-$194K	–	585
2021 Q1	$194K	Buy	+7,500	New	+$330K	0.01%	274
2020 Q4	–	Sell	-1,417	Closed	-$58K	–	396
2020 Q3	$58K	Buy	+1,417	New	+$61.2K	0.01%	293

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cowen and Company's ACAD Position: Q4 2021 in Review

Cowen and Company sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 5,121 shares — an estimated $85K sold.

Cowen and Company first reported a position in ACAD in Q3 2020 and held it in 3 quarters. The position peaked at $194K in Q1 2021. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

Cowen and Company reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Cowen and Company sold 5,121 Acadia Pharmaceuticals shares in Q4 2021, an estimated $85K.
Cowen and Company first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 3 quarters.
Cowen and Company's Acadia Pharmaceuticals position peaked at $194K in Q1 2021.
247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.